Compare HVT & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HVT | ENTA |
|---|---|---|
| Founded | 1885 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.9M | 378.0M |
| IPO Year | 1994 | 2012 |
| Metric | HVT | ENTA |
|---|---|---|
| Price | $27.36 | $13.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 132.7K | ★ 195.9K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.05% | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $758,995,000.00 | $102,814,000.00 |
| Revenue This Year | $8.83 | $7.76 |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $35.56 | ★ N/A |
| Revenue Growth | 4.99 | ★ 16.48 |
| 52 Week Low | $19.90 | $7.05 |
| 52 Week High | $29.83 | $17.15 |
| Indicator | HVT | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 50.26 |
| Support Level | $25.26 | $13.47 |
| Resistance Level | $29.83 | $13.98 |
| Average True Range (ATR) | 0.65 | 0.67 |
| MACD | -0.21 | 0.05 |
| Stochastic Oscillator | 40.46 | 36.99 |
Haverty Furniture Companies Inc is a specialty retailer of residential furniture and accessories. It provides various products such as Sofa Tables, Sleepers, End Tables, Cocktail Tables, Accent Pieces, Display Cabinets, Wall Decor, floral and Tress, and other related products. The company operates in the Southern and Midwestern U.S. All its activities are encompassed in its Merchandise division. The company derives the majority of revenue from its upholstery products and, secondarily, from bedroom furniture.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.